Biogen Inc.(BIIB)
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Latest News & Analysis
Biogen (BIIB): Breakthrough SLE Data & Strategic Collaborations
Biogen's dapirolizumab pegol shows promising Phase 3 SLE results, signaling a potential breakthrough in autoimmune treatments. Strategic collaborations and robust financials underscore its market position.
Biogen's Strategic Evolution: Pipeline Catalysts & Financial Resilience
Biogen's latest advancements in clinical trials, strategic collaborations, and financial performance underscore its transformative journey in neuroscience and immunology.
Biogen Inc. (BIIB): Strategic Pivot and Financial Resilience Analysis
Analyzing Biogen Inc.'s latest strategic pivot towards RNAi and Alzheimer's, its recent financial performance showing net income growth despite revenue pressure, and the impact of evolving US drug pricing policies.
Biogen: Alzheimer's Drug, Acquisition Strategy, and Pipeline Challenges
Biogen faces challenges in MS drug sales but sees potential in Alzheimer's treatment and strategic diversification. Key developments and market analysis.
Biogen (BIIB) Analysis: Leqembi, MS Drug Sales, and Financials
Biogen navigates strategic shifts with new HQ, Leqembi's Alzheimer's potential, and efforts to offset MS drug sales decline. Financial health and R&D are key.
Biogen (BIIB): Felzartamab, Stoke, and Growth Beyond MS
Biogen faces MS drug sales decline but seeks growth via pipeline diversification and strategic collaborations. Felzartamab, Leqembi, and Stoke partnership are key.
Biogen (BIIB): Strategic Shifts, Pipeline Developments, and Financial Outlook
Biogen (BIIB) is strategically shifting towards rare diseases, leveraging collaborations, and enhancing R&D efficiency, impacting its market position and financial outlook.
Biogen (BIIB) Stock Analysis: Pipeline Progress, Market Challenges, and Investment Outlook
Biogen (BIIB) faces challenges but strategic initiatives offer potential growth. Valuation suggests it may be undervalued, presenting a potential opportunity for investors.
Biogen's Strategic Pivot: Leqembi, Rare Diseases, and Financial Restructuring
Biogen navigates market shifts with Leqembi, rare disease focus, and financial restructuring. Analysts eye growth strategy amid stock fluctuations.
Biogen (BIIB): Leqembi, Stoke Collaboration, and Analyst Outlook
Biogen (BIIB) navigates a complex landscape with Leqembi's market uptake, strategic collaborations, and analyst outlook, influencing investment decisions and market positioning.
Biogen (BIIB): Navigating Market Challenges and Pipeline Opportunities
Analysis of Biogen's latest developments: Q4 2024 earnings, Leqembi's market performance, Zorevunersen collaboration, MS franchise challenges, and strategic initiatives.
Biogen (BIIB): Earnings, Leqembi, and the Path to Recovery
Biogen (BIIB) navigates a complex landscape of declining franchises, Leqembi's challenges, and strategic shifts. Collaborations and cost-cutting are key, but analyst sentiment is cautious.
Biogen's Strategic Shift: Navigating Challenges and Embracing New Opportunities
An in-depth analysis of Biogen's Q4 2024 performance, strategic partnerships, and market repositioning amid evolving industry challenges.
Biogen's Dravet Syndrome Deal: Zorevunersen’s Pipeline Strategy
An in-depth analysis of Biogen’s collaboration on Zorevunersen for Dravet Syndrome, Q4 earnings, and strategic pipeline developments.